BioInvent Outlines Strong Progress in Clinical and Preclinical Pipeline at R&D Day 2022 - Seite 3

The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com. Follow on Twitter: @BioInvent.

For further information, please contact:
Cecilia Hofvander, Senior Director Investor Relations
Phone: [phone]
Email: [e-mail]

BioInvent International AB (publ)
Co. Reg. No. Org nr: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: [phone]
www.bioinvent.com

The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.

Attachments

BioInvent Outlines Strong Progress in Clinical and Preclinical Pipeline at R&D Day 2022

SOURCE: BioInvent International

View source version on accesswire.com:
https://www.accesswire.com/730889/BioInvent-Outlines-Strong-Progress-i ...


The BioInvent International Stock at the time of publication of the news with a raise of +3,61 % to 3,445EUR on Gettex stock exchange (08. Dezember 2022, 13:13 Uhr).